Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(2.33) per share which missed the analyst consensus estimate of $(2.19) by 6.39 percent. This is a 66.43 percent decrease over losses of $(1.40) per share from the same period last year. The company reported quarterly sales of $9.839 million which missed the analyst consensus estimate of $13.048 million by 24.60 percent. This is a 84.57 percent decrease over sales of $63.745 million the same period last year.